



## Agentes implicados en el RRI: sector sanitario

RRI en España y su modelo de incorporación en los institutos de investigación sanitaria, Santander, 1 de julio

2019  
Galo Peralta. Director de Gestión IDIVAL  
Coordinador ITEMAS



*“In a context of global societal challenges, such as climate change or the ageing of our societies, broader societal involvement in R&I is needed to collaboratively reflect on the futures we aspire to as societies”. <https://www.rri-tools.eu/>*

	HAQ Index	Tuberculosis	Diarrhoeal diseases	LRIs	URLs	Diphtheria	Whooping cough	Tetanus	Measles	Maternal disorders	Neonatal disorders	NM skin cancer (SCC)	Breast cancer	Cervical cancer	Uterine cancer	Colon cancer	Testicular cancer	Hodgkin's lymphoma	Leukaemia	Rheumatic HD	Ischaemic HD	Stroke	Hypertensive HD	Chronic respiratory	Peptic ulcer	Appendicitis	Hernia	Gallbladder	Epilepsy	Diabetes	Chronic kidney	Congenital heart	Adverse med treat	
Iceland [1]	97	100	98	76	100	100	100	100	100	100	100	72	100	95	99	96	100	100	98	100	87	96	94	100	100	100	100	98	85	100	100	94	93	
Norway [2]	97	100	99	90	100	100	100	100	100	100	95	75	97	95	95	95	100	100	95	100	91	90	100	100	87	100	100	99	78	85	100	88	100	
Netherlands [3]	96	100	97	81	100	100	100	100	100	100	80	74	97	86	97	97	100	99	97	100	100	95	100	100	100	100	99	92	84	94	97	89	100	
Luxembourg [4]	96	100	90	99	100	100	99	100	100	100	99	67	99	82	100	99	100	100	97	89	99	97	92	100	100	100	98	96	84	100	88	100	77	
Australia [5]	96	100	96	93	100	100	100	100	100	100	83	100	99	69	86	100	100	100	99	97	96	100	100	91	100	100	100	99	88	89	87	87	88	
Finland [6]	96	100	100	100	100	100	100	100	100	100	100	71	100	100	91	92	95	98	90	100	78	84	77	100	81	100	99	96	84	85	100	88	100	
Switzerland [7]	96	100	90	98	100	100	100	100	100	100	81	77	93	78	94	99	82	95	97	100	98	100	92	100	100	100	100	99	95	100	99	86	100	
Sweden [8]	95	100	99	86	100	100	100	100	100	100	95	73	98	86	96	88	100	94	79	100	81	90	96	100	83	100	100	98	90	86	97	92	99	
Italy [9]	95	100	99	100	100	100	100	100	100	100	86	67	98	74	100	99	96	88	67	86	99	98	70	100	100	100	99	92	100	99	89	86	94	
Andorra [10]	95	100	96	81	100	100	97	100	100	100	98	58	97	94	97	95	99	99	98	99	85	98	91	74	87	100	99	95	85	94	100	81	92	
Ireland [11]	95	97	97	85	100	100	100	100	100	100	88	73	92	89	92	89	95	95	83	97	83	99	97	95	90	100	99	94	86	100	91	80	98	
Japan [12]	94	95	90	71	100	100	100	100	100	100	100	27	100	100	92	100	92	92	95	100	99	76	99	93	98	100	100	90	100	100	79	84	99	
Austria [13]	94	100	99	100	100	100	100	100	100	100	89	42	89	84	96	91	95	83	95	98	87	100	74	100	99	100	100	99	97	95	80	90	73	
Canada [14]	94	100	95	81	100	100	100	100	100	100	70	57	94	79	94	92	97	100	97	91	76	93	100	93	98	100	100	99	97	82	84	79	93	
Belgium [15]	93	100	91	74	100	100	100	100	100	100	86	60	94	79	94	93	97	95	88	93	91	92	99	96	94	100	98	94	78	99	92	93	74	
New Zealand [16]	92	100	91	100	100	100	100	100	100	96	76	95	89	84	78	88	86	89	90	74	83	93	98	85	100	100	100	97	82	91	70	78	100	
Denmark [17]	92	100	90	84	100	100	100	100	100	100	79	53	87	86	91	88	98	85	99	100	97	89	100	98	75	100	98	90	84	78	86	83	95	
Germany [18]	92	100	96	83	100	100	100	100	100	100	86	66	92	83	98	94	96	96	37	89	87	97	71	100	86	100	100	95	75	91	82	88	79	
Spain [19]	92	99	98	98	100	100	100	100	100	100	88	57	84	60	87	87	79	78	83	82	100	99	96	100	100	100	100	98	89	100	100	90	90	84
France [20]	92	99	89	89	100	100	100	100	100	100	84	62	89	79	87	86	90	86	69	91	100	100	98	100	100	100	99	97	79	96	99	83	63	
Slovenia [21]	91	99	100	98	100	100	100	100	100	100	97	56	83	88	93	78	84	73	94	81	95	87	68	100	88	100	95	88	93	100	100	92	51	
Singapore [22]	91	85	99	41	100	100	100	100	100	100	100	30	93	79	89	95	87	90	96	100	67	74	56	100	96	100	100	86	100	100	57	88	100	
UK [23]	90	100	94	68	100	100	100	100	100	100	78	80	85	77	93	87	99	94	96	97	85	90	84	80	76	100	87	81	71	93	100	72	84	



GBD 2015 Healthcare Access and Quality Collaborators. Electronic address:cjlm@uw.edu; GBD 2015 Healthcare GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018 Jun 2;391(10136):2236-2271..

# Investigación y salud

## España en el top 10

Rankings de Generación de conocimiento vs. inversión en I+D



	Country	Documents
1	United States	7.846.972
2	China	3.129.719
3	United Kingdom	2.141.375
4	Germany	1.983.270
5	Japan	1.929.402
6	France	1.421.190
7	Canada	1.110.886
8	Italy	1.083.546
9	India	868.719
10	Spain	857.158
11	Australia	782.149
12	South Korea	658.602
13	Russian Federation	639.598
14	Netherlands	614.552
15	Brazil	529.841
16	Taiwan	446.282
17	Switzerland	445.163
18	Sweden	417.156
19	Poland	387.982
20	Turkey	348.836

País	Inversión en I+D (%)
Suecia	3,45
Finlandia	3,43
Islandia	3,11
Dinamarca	3,09
Alemania	2,84
Austria	2,65
Francia	2,25
Bélgica	2,04
Holanda	2,04
Unión Europea	2,03
Estonia	1,81
Reino Unido	1,73
Irlanda	1,72
Noruega	1,70
Rep. Checa	1,57
Portugal	1,42
España	1,33
Italia	1,25
Hungría	1,21
Lituania	0,92
Polonia	0,77
Letonia	0,70
Eslovaquia	0,68

España. 10º país en producción Científica mundial

**SJR**

SCImago Journal & Country Rank

# Agentes implicados en el RRI

## Sector sanitario




<http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml>









# Agentes implicados en el RRI

## Sector sanitario +++

- I+I dirigida a los pacientes
  - Investigación traslacional: biomarcadores, devices, nuevas drogas...
  - Ensayos clínicos
  - Innovación: asistencia y transferencia
- I+I desarrollada sobre pacientes
  - Intervención en pacientes
  - Muestras de pacientes
  - Datos de pacientes
- I+I (y sanidad) financiada por pacientes
  - Sistema público
  - Universal



<https://www.rri-tools.eu>



# Informamos de la actividad

## Producción científica

### RESEARCH ARTICLE SUMMARY

#### PSYCHIATRIC GENOMICS

## Analysis of shared heritability in common disorders of the brain

The Brainstorm Consortium†

**INTRODUCTION:** Brain disorders share symptoms and suicidal comorbidity, inciting etiologic overlap. However, phenotypes with different etiology, and presentation poses a challenge. Recently developed methods allow us to accurately measure genome-wide common variants shared between disorders.

## Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study

Alexandra Djalil, Heekyoung Ahn, Aron Cook, Rodger Lohman, Alexander Dink, Akshay Bhatia, Penelope Charles, Cecilia Marelli, Gabriela Mariani, Lorenza Nardelli, Maria Pagan, Maria Ralwiczka, Anna Sobotnik, Anna Sokol, Tanja Schmitt, Hilbert Lindner, Ludwig Schöls, Holger Vogel, Beate Wildgen, Alexander Wolf, Anirudh Aravamudan, Jan Inge Jørgensen, José Benito, Beat Fiume de Warentzen, Dagmar Timmerman, Sylvio Bessich, Massimo Pandolfo, Jörg H Schulz, Peter Bauer, Paolo Giunti, Jun-Sik Kang, Thomas Klöpper, Heide Siebert, and Antonio de Mendonça

Correspondence



## Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to B Disease

José Luis Martín-Villas, MD, PhD, Vanesa Ceballos-Río, MD, PhD, Emma Belletti, MD, PhD, Juan Sánchez-Bertrán, MD, PhD, Mireia Mesquida, MD, PhD, Alfredo Aláiz, MD, PhD, María Victoria Hernández, MD, PhD, Maria Hernandez-Cereceda, MD, PhD, Eka Vale Pascual, MD, PhD, Lucía Martínez-Costa, MD, PhD, Agustín Salas-Fernández, MD, PhD, Miguel González-Correa, MD, PhD, Manuel Díaz-López, MD, PhD, Roberto Gallego, MD, PhD, David Salom, MD, PhD, Norberto Ortega, MD, PhD, José L. García-Serrano, MD, PhD, José-Luis Calleja-Rufo, MD, PhD, José M. Hervas, MD, PhD, Ángel García-Aparicio, MD, PhD, Olga Muñoz, MD, PhD, Ana Bláquez, MD, PhD



Available online at www.sciencedirect.com

ScienceDirect



## α-synuclein (SNCA) but not dynamin 3 (DNM3) Influences Age at Onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's Disease in Spain

Rubén Fernández-Santiago, PhD, Alicia Gantto, MD, Jon Infante, MD, PhD, Isabel González-Aramburu, MD, María Sierra, MD, PhD, Manel Fernández, Francisco Valdeolmillos, MD, PhD, Esteban Muñoz, MD, PhD, Yaroislau Compta, MD, PhD, María-José Martí, MD, PhD, José Ríos, MSc, Eduardo Tolosa, MD, PhD, Mario Ezequerra, PhD, and



### LETTERS

https://doi.org/10.1038/s41588-018-0142-8

... can lead to premature ocular ataxia (SCA), SCA2, or SCA3.

... aged 18 years or older from their test results for SCA1, SCA2, or SCA3. We used a nomogram and assessed their registered with ClinicalTrials.gov.

SCA2 (n=162), SCA3 (n=139), or

## Messages from the voices within: regulation of signaling by proteins of the nuclear lamina

Larry Gerace<sup>1</sup> and Olga Tapia<sup>1,2</sup>

The nuclear lamina (NL) is a protein scaffold lining the nuclear envelope that consists of nuclear lamins and associated transmembrane proteins. It helps to organize the nuclear envelope, chromosomes, and the cytoplasmic cytoskeleton. The NL also has an important role in regulation of signaling, as highlighted by the wide range of human diseases caused by mutations in the genes for NL proteins with associated signaling defects. This review will consider diverse mechanisms for signaling regulation by the NL that have been uncovered recently, including interaction with signaling molecules, regulation of cell death and differentiation.

NL also contains numerous less abundant membrane proteins that directly or indirectly associate with lamins. Three major lamin subtypes are present in mammals: B1 and B2, which are the most abundant, and B3, which is the least abundant. Products of alternative splicing during differentiation.

The NL has attracted widespread interest because of its expansive functional repertoire. It

## Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PCa) susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PCa cases and 27,910 controls of European ancestry with previously

## Dilated Cardiomyopathy Due to BLC2-Associated Athanogin 3 (BAG3) Mutations

Fernando Danzi, Eric Willard, PhD, Arjan Samadpour, PhD, Diego Ballester-Sa, José Manuel García Ana Román-Sa, David de González Salazar, Philippe Claeys, for the European ESC European Society of Cardiology, FASTTRACK CLINICAL RESEARCH, Coronary

## Clinical use of intracoronary imaging. Par guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions

Endorsed by the Chinese Society of Cardiology

Lorenz Räber<sup>1</sup>, Gary S. Mintz<sup>2</sup>, Konstantinos C. Koskinas<sup>3</sup>, Thomas W. J. Niels R. Holm<sup>4</sup>, Yoshinobu Onuma<sup>5</sup>, María D. Radu<sup>6</sup>, Michael Joner<sup>7</sup>, Bo Høiboja<sup>8</sup>, Nicola Meneveau<sup>9,10</sup>, José M. de la Torre Hernandez<sup>11</sup>, Javier Escaned<sup>12</sup>, Jonathan Hill<sup>13</sup>, Francesco Prati<sup>14</sup>, Antonio Colombo<sup>15</sup>, Carlo Evelyn Rega<sup>16</sup>, Davide Capodanno<sup>17</sup>, William Wijns<sup>18</sup>, Robert A. Byrne<sup>19</sup>, Giulio Gagliardi<sup>20</sup>

Coordinating editor: Prof Patrick W. Serruys, MD, PhD, Imperial College, London, UK. Document Reviewers: Fernando Alfonso<sup>21</sup>, Ravin Shah<sup>22</sup>, Ziad Alr<sup>23</sup>, Rickey Carter<sup>24</sup>

## Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse

Isabel Zepeda-Rodríguez, MD, PhD, Adriel de Alencar, MD, PhD, Patrícia Matos, MD, PhD, Manuel Martínez-Solís, MD, PhD, Víctor González-Ramallo, MD, PhD, Jose M. Sierra, MD, PhD, Carlos Palome, MD, PhD, Claudia González-Ríos, MD, PhD, Xavier Montojano-Urbeola, MD, PhD, José Antonio Lopez, MD, PhD, Rogelio Rodríguez Álvarez, MD, PhD, Jose María Biquerra Iglesias, MD, PhD, Estrope Navas, MD, PhD, Fernando Dominguez, MD, PhD, Pablo García-Pavía, MD, PhD, for the Spanish Collaboration on Bicuspid Aortic Valve and Mitral Valve Prolapse (CIBAVM)

### ABSTRACT

**BACKGROUND:** There is little information concerning infective endocarditis (IE) in patients with bicuspid aortic valve (BAV) or mitral valve prolapse (MVP). Currently, echocardiographic paravalvular (ECP) is not recommended for these conditions.

**OBJECTIVES:** This study sought to describe the clinical and microbiological features of IE in patients with BAV and MVP and compare them with those of IE patients with and without EAP indicators. To determine the potential benefit of EAP

### PERSPECTIVE

## Mammalian endoreplication emerges to reveal a developmental timer

Alberto Gandarillas<sup>1,2</sup>, Rut Molinero<sup>1</sup>, Natalia Sanz-Gómez<sup>2</sup>

2017 / Revised 7 November 2017 / Accepted 8 November 2017  
This article is published with open access

Intriguing and relevant to the field, endoreplication typically occurs in a wide range of organisms, from yeast to mammals. In mammals, endoreplication is typically observed in the developing embryo, but its function remains unclear. Here, we show that endoreplication is essential for the differentiation and carcinogenesis of the developing embryo.

### Open

## Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm

Antonio Cuadrado, MD, PhD, Susana Llerena, MD, PhD, Carmen Cobo, MD, PhD, José Ramón Pallás, MD, Miguel Mateo, MD, Joaquín Cabezas, MD, PhD, José Ignacio Fortea, MD, PhD, Silvia Alvarez, MD, PhD, Raúl Pellón, MD, Juan Crespo, MD, Santiago Echevarría, MD, PhD, Rosa Ayres, MD, PhD, Esther Sellés, MD, PhD, Marcos Lopez Hoyos, MD, PhD, Benedicto Crespo-Facorro, MD, PhD, Jesus Agüero, MD, PhD, Natalia Chucua, MD, PhD, Federico Garcia, MD, PhD, Jose Luis Calleja, MD, PhD, and Javier Crespo, MD, PhD

### OBJECTIVES:

Prisons are major reservoirs of hepatitis C virus (HCV) in which a therapeutic approach has been particularly difficult so far. Our aim was to create a permanent program of HCV elimination in a prison based on a "test and treat" strategy.

### METHODS:

This open-label clinical trial was conducted in the Spanish prison "El Dueso" between May 2016 and July 2017. Viremic patients were treated with a ledipasvir-sofosbuvir regimen (8-12 weeks) according to the 2015 Spanish Guidelines. A teleconsultation program was established to follow-up

## NEWS & VIEWS

### VASCULITIS SYNDROMES

## A closer look at skin involvement in vasculitis

Javier Loricera and Ricardo Blanco

A detailed report on the involvement of skin in vasculitis enriches existing disease definitions and nomenclature, and could improve the diagnosis of these manifestations. The review also emphasizes the need for collaboration across different medical specialties in the study of vasculitis.

involvement of the skin being a frequent clinical feature of vasculitis, either as a single clinical manifestation or in the setting of a disease with systemic involvement.

In an effort to standardize the names and definitions of cutaneous vasculitis, Sunderkotter et al. have now added a dermatological addendum to the 2012 CHCC criteria with the characteristics of the cutaneous involvement in the different types of vasculitis. The authors make an elegant tour around the various types of vasculitis, pointing out in each of them the most characteristic dermatological findings, albeit most manifestations of vasculitis are confined to the skin, including panniculitis and mucosa definition of skin. In addition, categories (such as cutaneous immune complex vasculitis) included in the CHCC criteria

### LIVER

# Agentes implicados en el RR Sector sanitario +++



**Debby Keller, MD**

@debby\_keller

Assistant Professor of Surgery and  
Surgical Outcomes Researcher

@nyhospital @ColumbiaCRS  
@ColumbiaSurgery #colorectalsurgery  
#colorectalsurgery #crstrial

📍 New York, NY



**Debby Keller, MD**

@debby\_keller

Follow

## Of Scientists and Tweets @NatureRevCancer

@me4\_so @soragnilab @Aaims1742  
[nature.com/articles/s4156...](https://nature.com/articles/s4156...)

MENU ▾ **nature REVIEWS CANCER**

Comment | Published: 28 June 2019

## Of scientists and tweets

Alice Soragni<sup>1</sup> & Anirban Maitra<sup>2</sup>

Nature Reviews Cancer (2019) | Download Citation ↓

Over the past few years, Twitter has burgeoned as a freely available worldwide platform for rapid dissemination of published and unpublished research advances, an avenue to foster collaborations without traditional boundaries and a means to educate both scientific and lay audiences.

### Access options

#### Rent or Buy article

Get time limited or full article access on ReadCube.

from **\$8.99**

Rent or Buy

All prices are NET prices.

#### Subscribe to Journal

Get full journal access for 1 year

**75,02 €**  
only 6,25 € per issue

Subscribe

All prices include VAT for Spain.

### Of scientists and tweets

Alice Soragni<sup>1</sup> and Anirban Maitra<sup>2</sup>

Over the past few years, Twitter has burgeoned as a freely available worldwide platform for rapid dissemination of published and unpublished research advances, an avenue to foster collaborations without traditional boundaries and a means to educate both scientific and lay audiences.



**How Twitter has changed the game**  
One of the central tenets of the scientific method is to disseminate research findings widely to the scientific community. This is typically done through peer-reviewed journals, which are then disseminated to the wider scientific community through various channels. However, the traditional model of dissemination is being challenged by the rise of social media, particularly Twitter. This article explores how Twitter has changed the game of scientific communication, from the way research is disseminated to the way it is received and discussed. We discuss the impact of Twitter on the scientific community, the challenges it presents, and the opportunities it offers. We also explore the role of Twitter in the broader context of scientific communication and the future of the field.

**Why we tweet?**  
With over 280 million active users, Twitter is the world's second largest social media platform. It is a platform where scientists can share their research findings, engage with their colleagues, and reach a wider audience. This article explores the reasons why scientists use Twitter and the benefits it offers. We discuss the impact of Twitter on the scientific community, the challenges it presents, and the opportunities it offers. We also explore the role of Twitter in the broader context of scientific communication and the future of the field.

**Key takeaways**  
• Twitter is a powerful tool for disseminating research findings and engaging with the scientific community.  
• It offers a faster and more direct way to reach a wider audience compared to traditional channels.  
• It provides a platform for scientists to share their research, discuss their findings, and collaborate with their colleagues.  
• It is a valuable resource for staying up-to-date on the latest research and developments in the field.


# Agentes implicados en el RRI

## Sector sanitario +++



# Agentes implicados en el RRI


## Sector sanitario +++



Fuente: EPSCYT 2016, FECYT



# Agentes implicados en el RRI

## Sector sanitario +++





# Agentes implicados en el RRI

## Sector sanitario +++



# Agentes implicados en el RRI

## Sector sanitario ¿+++?



Science Home News Journals Topics Careers

CALL FOR PAPERS SPJ

Research Welcoming Life Science Submissions

OPEN ACCESS

Submit today »

Log in | My account

## Suspect Drug Research Blamed for Massive Death Toll

Gretchen Vogel

+ See all authors and affiliations

Science 31 Jan 2014:  
Vol. 343, Issue 6170, pp. 473-474  
DOI: 10.1126/science.343.6170.473

Article

Figures & Data

Info & Metrics

eLetters

 PDF

You are currently viewing the summary.

[View Full Text](#)




### Summary

An article published earlier this month on the website of the *European Heart Journal* claimed that European guidelines on the use of  $\beta$  blockers in surgery patients are flawed because two of the trials underpinning them were led by a researcher who was fired for misconduct in 2011. As a result, 800,000 people may have died, according to the paper, which was removed from the journal's website less than 48 hours after publication.

# Agentes implicados en el RRI

## Sector sanitario ¿+++?


- I+D conocida por los pacientes?
  - Consentimiento informado
  - Proyectos y resultados accesibles
  - Resultados comprensibles
- I+D priorizada con los pacientes?
- I+D codiseñada por pacientes?
- I+D desarrollada con los pacientes
  - Participación en los equipos de I+D
  - Participación activa: recogida de datos, seguimiento, identificación de barreras
- I+D con la opinión del paciente?
  - Impacto



# Agentes implicados en el RRI


## Sector sanitario ¿+++?

- **Información pública de ensayos clínicos**
  - Hospitales USA 15/15 tops
  - Hospitales Españoles 1/15
- **Información pública de sus profesionales**
  - Hospitales USA 15/15
  - Hospitales Españoles 1/15
- **Información pública estructuras de I+D**
  - Hospitales Americanos ?/15
  - Hospitales Españoles 15/15: *IIS*
- **Información agregada pública**
  - Hospitales USA: OK



# Agentes implicados en el RRI


## IIS: agentes claves




Hospital Universitario Marqués de Valdecilla

[Inicio](#) [Asistencial](#) [Formación](#) [Investigación](#) [RR.HH.](#) [Gestión](#) [Biblioteca Virtual](#)

[IDIVAL](#)





### Menú General

- Principal
- Atención al Usuario
- Urgencias Informa


### Menú de Empleados

- Correo
- Manual Correo
- Foros
- Intranet
- Sindicatos
- Solicitud de Cursos

**NOTIFICACIONES**  
SINASP TARJETA AMARILLA





### Uso Interno

- Portal del Empleado

 **Tablón de RR.HH.**

Administradores +

**VPN-SSL**



### Últimas noticias

#### Enfermería

- Tres comunicaciones premiadas en el X Cong. Esp. de Lactancia Materna
- Libro Ponencias y Comunicaciones VI Jornadas Innovación y Desarrollo
- La Unidad de Formación de Enfermería obtiene la Acreditación de la CFC
- Boletín Enfermería Valdecilla Junio-Julio 2019

#### Médica













- El Dr. Ramón Agüero Balbín recibe el Premio Médico-Médico en el Congreso SEPAR 2019.
- Premio a la Dra Corriols del Servicio de ORL
- Acreditación de la Sociedad Española de Oncología Médica para la Dra. Carmen Hinojo González
- El Dr. Marcos López Hoyos es proclamado Presidente entrante de la SEI
- 2º premio en el XVI congreso de la Sociedad Española de Radiología Vasculare e Intervencionista
- Premios recibidos en el XXXVIII Congreso SOCALPAR de Zamora los días 10 y 11 de abril
- Premios de la U. Docencia Médica en la I Jornada del Residente Investigador HUMV del 10/04/2019
- El Dr Casanova del HUMV nombrado Presidente de Honor de la División Europea de Trasplante de la UEMS
- Premio a la mejor comunicación oral obtenido en la 19ª edición del Congreso Nacional Neuroraquis

#### Sesiones Generales

- a partir de Julio hasta el 19 de septiembre no hay sesiones generales


▸ Revista Médica Valdecilla

**Videos:** Sesiones Clínicas y Videos: WebTV  
Videos de Enfermería



# Agentes implicados en el RRI


## Sector sanitario ¿+++?



# Agentes implicados en el RRI

## Sector sanitario ¿+++?

- Información agentes implicados
  - Paciente
  - Personal sanitario
  - Gestores
  - Políticos
- Redundancias
  - Diferentes bases de datos
  - Diferente colecciones de muestras
- Costes?
- Conflictos de intereses
  - Curricular: investigadores
  - Desarrollo de producto: privados
- Control de calidad I+D
- Impacto




- Sistemas de información
- Aprendizaje
- Cultura
- Recursos específicos

# RRI como reto

## Sector sanitario en marcha con los IIS

- Información disponible
  - Proyectos
  - Ensayos
  - Curriculum
  - Producción científica
- Acceso abierto como prioridad
  - Repositorios
  - Open access
- Campañas de colaboración
  - Micromecenazgo
- Co-creación
  - Design thinking
- Programas de talento inclusivo
  - HRS4R
  - Planes de igualdad





# UN PROGRAMA DEL SERVICIO CÁNTABRO DE SALUD

MEJORA EL DÍA A DÍA DE TU TRABAJO  
APORTANDO TU VISIÓN Y EXPERIENCIA

[PARTICIPA](#)



# Institutos de Investigación Sanitaria

## Retorno socioeconómico

---

La posteridad duradera de las naciones es obra de la ciencia y de sus múltiples aplicaciones al fomento de la vida y los intereses materiales.

1898, Santiago Ramón y Cajal



Galo Peralta  
Director de Gestión IDIVAL  
Coordinador ITEMAS  
[dirección@idival.org](mailto:dirección@idival.org)  
@IDIVALdirección  
[www.idival.org](http://www.idival.org)  
[www.itemas.org](http://www.itemas.org)